What We're Reading
Industry reads hand-picked by our editors
Sep 26, 2023
-
Reuters
Ionis’ metabolic disorder drug lowers high levels of a type of fat in study
-
FirstWord Pharma
Takeda partners with AcuraStem on ALS drug development
-
Financial Times
Covid antiviral drug linked to ‘transmissible’ mutations, research finds
-
The Wall Street Journal
The Band of Debunkers Busting Bad Scientists
Sep 25, 2023
Sep 22, 2023
Sep 21, 2023
-
STAT News
They carry a gene for ALS but aren’t sick. What does medical research owe them?
-
Bloomberg Law
Drugmakers Aren’t Waiting Around for Details on Medicare Tax
-
Reuters
India’s Glenmark to sell majority stake in life sciences unit for $680 million
-
MIT Technology Review
DeepMind is using AI to pinpoint the causes of genetic disease
Sep 20, 2023
-
Reuters
U.S. FDA found lapses at Novo’s main U.S. factory in May 2022
-
NBC News
FDA rejects first needle-free alternative to EpiPens, calling for additional research
-
The New York Times
How Much Do Patients Need to Know About a Potentially Risky Treatment?
-
The Washington Post
Inside the gold rush to sell cheaper imitations of Ozempic
Sep 19, 2023
-
Wired
Crispr Pioneer Jennifer Doudna Has the Guts to Take On the Microbiome
-
The Washington Post
How one company profited while delaying Narcan’s drugstore debut
-
Nature
AI can help to speed up drug discovery — but only if we give it the right data
-
The Wall Street Journal
Bankrupt Drugmaker Mallinckrodt Considers Sale of Opioid Business
